Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

synthetic MVA-based SARS-CoV-2 vaccine COH04S1

A vaccine comprised of a synthetic modified Vaccinia virus Ankara (sMVA) viral vector encoding the two severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) surface antigens spike (S) and nucleocapsid (N) proteins, with potential immunizing activity against SARS-CoV-2. Upon administration of the sMVA-based SARS-CoV-2 vaccine COH04S1, the SARS-CoV-2 S and N proteins are expressed in cells and presented to the immune system. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	SARS-CoV-2 vaccine COH04S1 sMVA-based SARS-CoV-2 vaccine COH04S1
Code name:	COH04S1

synthetic MVA-based SARS-CoV-2 vaccine COH04S1

Search NCI's Drug Dictionary